litlas
Log inCreate account

Igor Puzanov

Active 1996–2025

147
Papers
52,627
Citations
90
h-index
144
i10-index

Citations

Citations per year for Igor Puzanov1997: 7 citations1998: 13 citations1999: 16 citations2000: 17 citations2001: 23 citations2002: 20 citations2003: 14 citations2004: 10 citations2005: 11 citations2006: 15 citations2007: 7 citations2008: 24 citations2009: 54 citations2010: 136 citations2011: 288 citations2012: 457 citations2013: 564 citations2014: 595 citations2015: 698 citations2016: 778 citations2017: 952 citations2018: 988 citations2019: 2,692 citations2020: 3,019 citations2021: 2,713 citations2022: 2,000 citations2023: 1,440 citations2024: 2,049 citations2025: 980 citations2026: 33 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,058 citing papers, 29.6% of this breakdownChina: 2,413 citing papers, 10.1% of this breakdownItaly: 1,321 citing papers, 5.5% of this breakdownUnited Kingdom: 1,268 citing papers, 5.3% of this breakdownGermany: 1,240 citing papers, 5.2% of this breakdownFrance: 1,201 citing papers, 5% of this breakdownAustralia: 848 citing papers, 3.6% of this breakdownCanada: 766 citing papers, 3.2% of this breakdownSpain: 730 citing papers, 3.1% of this breakdownJapan: 701 citing papers, 2.9% of this breakdownNetherlands: 679 citing papers, 2.8% of this breakdownSwitzerland: 616 citing papers, 2.6% of this breakdown
0%29.6%Other 21.1%

Institutions

Fields

  • Medicine62.9%
  • Biochemistry, Genetics and Molecular Biology26.1%
  • Immunology and Microbiology7%
  • Computer Science0.8%
  • Engineering0.7%
  • Neuroscience0.6%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers13.2%
  • CAR-T cell therapy research5.9%
  • Melanoma and MAPK Pathways5.5%
  • Immunotherapy and Immune Responses5.1%
  • Cutaneous Melanoma Detection and Management2.7%
  • Immune Cell Function and Interaction2.5%
  • Other65.1%

Coauthors

All papers

Open in search
  1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson - Journal of Clinical Oncology 2018 cited by 3,697

  2. Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    Authors: Douglas B. Johnson, Justin M. Balko, Margaret Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R. Alexander, Tyler Bloomer, Jason R. Becker, David Slosky, Elizabeth J. Phillips, Mark A. Pilkinton, Laura Deeanne Craig-Owens, Nina Kola, Gregory E. Plautz, Daniel S. Reshef, Jonathan S. Deutsch, Raquel P. Deering, Benjamin A. Olenchock, Andrew H. Lichtman, Dan M. Roden, Christine E. Seidman, Igor J. Koralnik, Jonathan G. Seidman, Robert Hoffman, Janis M. Taube, Luis A. Díaz, Robert A. Anders, Jeffrey A. Sosman, Javid J. Moslehi - New England Journal of Medicine 2016 cited by 2,276

  3. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Authors: Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. S̄pitler, Igor Puzanov, Sanjiv S. Agarwala, Mohammed Milhem, Lee D. Cranmer, Brendan D. Curti, Karl D. Lewis, Merrick I. Ross, Troy H. Guthrie, Gerald P. Linette, Gregory A. Daniels, Kevin J. Harrington, Mark R. Middleton, Wilson H. Miller, Jonathan S. Zager, Yining Ye, Bin Yao, Li Ai, Susan Doleman, Ari M. Vanderwalde, Jennifer Gansert, Robert S. Coffin - Journal of Clinical Oncology 2015 cited by 2,598

  4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Authors: Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2021 cited by 826

  5. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Authors: Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari M. Vanderwalde, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fernández, John M. Kirkwood, Thomas F. Gajewski, Lisa Chen, Kevin Gorski, Abraham Anderson, Scott J. Diede, Michael E. Lassman, Jennifer Gansert, F. Stephen Hodi, Georgina V. Long - Cell 2017 cited by 1,506

  6. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    Authors: on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, Cynthia F. Brogdon, Ramona Dadu, Lamya Hamad, Sungjun Kim, Mario E. Lacouture, Nicole R. LeBoeuf, Dan Lenihan, C.D. Onofrei, Vickie R. Shannon, Rajeev Sharma, Ann W. Silk, Dimitra Skondra, María E. Suarez‐Almazor, Yinghong Wang, Kathleen E. Wiley, Howard L. Kaufman, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2017 cited by 1,984

  7. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Authors: David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean‐Yves Blay, Jürgen Wolf, Noopur Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoîne Italiano, Ralf‐Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schüler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzén, Maria Luisa Veronese, Josep Tabernero, José Baselga - New England Journal of Medicine 2015 cited by 1,734

  8. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    Authors: Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin - New England Journal of Medicine 2018 cited by 1,321

  9. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

    Authors: Jason Chesney, Antoni Ribas, Georgina V. Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Höeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes V. van Thienen, Sebastian Haferkamp, Josep Malvehy, Bernardo L. Rapoport, Ari M. Vanderwalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, F. Stephen Hodi, Helen Gogas - Journal of Clinical Oncology 2022 cited by 284

  10. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    Authors: Douglas B. Johnson, Mónica V. Estrada, Roberto Salgado, Violeta Sánchez, Deon B. Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate, Melinda E. Sanders, Christine M. Lovly, Dennie T. Frederick, Mark C. Kelley, Ann Richmond, Jonathan M. Irish, Yu Shyr, Ryan J. Sullivan, Igor Puzanov, Jeffrey A. Sosman, Justin M. Balko - Nature Communications 2016 cited by 572

  11. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    Authors: Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Alain P Algazi, Omid Hamid, Christopher D Lao, Stergios J Moschos, Michael B Atkins, Karl Lewis, Michael A Postow, Reena P Thomas, John Glaspy, Sekwon Jang, Nikhil I Khushalani, Anna C Pavlick, Marc S Ernstoff, David A Reardon, Ragini Kudchadkar, Ahmad Tarhini, Caroline Chung, Corey Ritchings, Piyush Durani, Margarita Askelson, Igor Puzanov, Kim A Margolin - The Lancet Oncology 2021 cited by 322

  12. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Authors: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 cited by 2,798

  13. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Authors: Suzanne L. Topalian, Mario Sznol, David F. McDermott, Harriet M. Kluger, Richard D. Carvajal, William H. Sharfman, Julie R. Brahmer, Donald P. Lawrence, Michael B. Atkins, John D. Powderly, Philip D. Leming, Evan J. Lipson, Igor Puzanov, David C. Smith, Janis M. Taube, Jon M. Wigginton, Georgia Kollia, Ashok Gupta, Drew M. Pardoll, Jeffrey A. Sosman, F. Stephen Hodi - Journal of Clinical Oncology 2014 cited by 2,207

  14. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

    Authors: Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul Lin, Richard J. Lee, Joseph F. Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, K. B. Nolop - Nature 2010 cited by 1,837

  15. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

    Authors: William D. Tap, Zev A. Wainberg, Stephen P. Anthony, Prabha N. Ibrahim, Chao Zhang, John H. Healey, Bartosz Chmielowski, Arthur P. Staddon, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Arun S. Singh, Igor Puzanov, Eunice L. Kwak, Andrew J. Wagner, Daniel D. Von Hoff, Glen J. Weiss, Ramesh K. Ramanathan, Jiazhong Zhang, Gaston Habets, Ying Zhang, Elizabeth A. Burton, Gary C. Visor, Laura Sanftner, Paul Severson, Hoa Nguyen, Marie J. Kim, Adhirai Marimuthu, Garson Tsang, Rafe Shellooe, C. M. Gee, Brian L. West, Peter Hirth, K. B. Nolop, Matt van de Rijn, Henry H. Hsu, Charles Peterfy, Paul Lin, Sandra Tong-Starksen, Gideon Bollag - New England Journal of Medicine 2015 cited by 582

  16. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Authors: Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 cited by 1,564

  17. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Authors: Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe, Theodore F. Logan, Axel Hauschild, Célèste Lebbé, Lisa Chen, Jaeyeon Kim, Jennifer Gansert, Robert H.I. Andtbacka, Howard L. Kaufman - Journal of Clinical Oncology 2017 cited by 617

  18. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

    Authors: Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Peter J. O’Dwyer, Richard J. Lee, Joseph F. Grippo, K. B. Nolop, Paul B. Chapman - New England Journal of Medicine 2010 cited by 3,536

  19. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

    Authors: Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito - Nature Communications 2021 cited by 187

  20. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

    Authors: Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe, Theodore F. Logan, Axel Hauschild, Célèste Lebbé, Harshada Joshi, Wendy Snyder, Janice M. Mehnert - Journal for ImmunoTherapy of Cancer 2023 cited by 89

  21. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Authors: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 cited by 2,148

  22. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

    Authors: Igor Puzanov, Mohammed Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael Chastain, Kevin Gorski, Abraham Anderson, Jeffrey Chou, Howard L. Kaufman, Robert H.I. Andtbacka - Journal of Clinical Oncology 2016 cited by 550

  23. Managing Metastatic Melanoma in 2022: A Clinical Review

    Authors: Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff - JCO Oncology Practice 2022 cited by 190

  24. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Authors: Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott, Matteo S. Carlino, Nikhil I. Khushalani, Fei Ye, Alexander Guminski, Igor Puzanov, Donald P. Lawrence, Elizabeth I. Buchbinder, Tejaswi Mudigonda, Kristen Spencer, Carolin Bender, Jenny Lee, Howard L. Kaufman, Alexander M. Menzies, Jessica C. Hassel, Janice M. Mehnert, Jeffrey A. Sosman, Georgina V. Long, Joseph I. Clark - JAMA Oncology 2015 cited by 656